Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Gastroenterology · Colon Cancer

What Happens if Invasive Cancer is Found in a Colon Polyp?

At a Glance

When invasive cancer is found in a removed colon polyp, the need for more treatment depends on the pathology report. Clear margins, shallow invasion, and no high-risk features may allow close colonoscopy surveillance; high-risk or unclear findings often lead to bowel surgery.

When a polyp is removed during a colonoscopy and the pathology report shows invasive cancer (making it a “malignant polyp”), it means that cancer cells have started to grow beyond the outermost layer of the colon lining. Finding cancer cells in a polyp can be frightening. If the polyp was completely removed, that is a major first step, but a visual removal during a colonoscopy does not guarantee microscopic clearance. What happens next depends heavily on specific details in the pathology report. Your medical team will analyze the exact features of the cancer cells, how deeply they invaded, and how the polyp was removed to decide whether endoscopic surveillance is sufficient or if surgical bowel resection is recommended.

Understanding the Pathology: Dysplasia vs. True Cancer

To understand your diagnosis, it helps to know how polyps grow and the anatomy of the colon wall.

The inner lining of the colon is called the mucosa. Beneath the mucosa is a supportive layer called the submucosa, which contains a rich network of blood vessels and lymphatic channels that lead to regional lymph nodes in the surrounding tissues.

If a pathology report mentions high-grade dysplasia or intramucosal neoplasia (sometimes called intramucosal carcinoma), it means abnormal cells are present, but they are entirely confined to the top mucosal layer [1] [2]. Because the mucosa lacks the larger lymphatic channels found deeper down, these cells have a negligible potential to spread to lymph nodes. In these cases, complete removal of the polyp is generally considered a cure, provided the margins are clear.

True invasive cancer (often staged as pT1 colorectal cancer) means the cancer cells have broken through the muscularis mucosae (the thin muscle layer separating the mucosa and submucosa) and entered the submucosa [1]. Once in the submucosa, cancer cells can access the lymph and blood vessels, introducing a risk that microscopic cancer cells may have traveled to local lymph nodes or remained in the colon wall [2].

Key Features the Pathologist Looks For

When invasive cancer is found, a pathologist examines the tissue under a microscope to assess the risk of the cancer spreading or returning. They look for several specific features:

  • Margin Status: The margin is the tissue at the very edge of where the polyp was cut away. Pathologists look at both the deep (vertical) margin and the lateral margins. A positive margin (tumor at the cautery edge) means cancer cells extend all the way to the cut edge, which is a high-risk feature [3]. A negative (clear) margin means there is a buffer of healthy tissue. Many guidelines consider a margin clear if there is at least 1 millimeter of healthy tissue, but exact interpretations vary based on the specific guideline and the specimen quality [4].
  • Depth of Invasion: For polyps on a stalk (pedunculated polyps), doctors use the Haggitt levels (1 through 4). Haggitt level 3 means the cancer invaded into the stalk. Haggitt level 4 means the cancer invaded through the stalk and into the submucosa of the underlying colon wall, which is considered high risk [5] [6]. For flat (sessile) polyps, the Kikuchi levels (SM1, SM2, SM3) or a precise measurement in micrometers (e.g., greater than 1000 micrometers) are used [7]. Deeper invasion carries a higher risk of lymph node involvement [8].
  • Lymphovascular Invasion (LVI): This indicates whether cancer cells are seen inside the tiny blood or lymph vessels within the polyp. The presence of LVI strongly increases the risk that cancer may have spread to nearby lymph nodes [9] [7].
  • Differentiation: This describes how much the cancer cells look like normal colon cells. “Well” or “moderately” differentiated cells look somewhat normal and tend to grow slower. “Poorly” differentiated cells look very abnormal, grow aggressively, and are considered high risk [9].
  • Tumor Budding: This refers to single cancer cells or small clusters of cells that are detaching from the main tumor. High-grade tumor budding is an adverse sign that the cancer is more likely to spread [9] [7].

En Bloc vs. Piecemeal Resection

How the gastroenterologist removed the polyp heavily impacts the pathologist’s ability to assess the tissue.

  • En Bloc Resection: The polyp was removed in one single, intact piece. This allows the pathologist to clearly see all the margins and accurately measure the depth of invasion [10].
  • Piecemeal Resection: The polyp was removed in multiple pieces. Fragmentation makes it very difficult for the pathologist to confidently assess the deep margin or the true depth of the cancer. Because it is harder to be certain the cancer was completely removed, piecemeal resection of an invasive cancer prompts careful reassessment and expert review [11] [12]. While not an automatic mandate for surgery in every single case, an unassessable margin due to piecemeal removal is treated as a higher-risk situation.

Next Steps: Review, Staging, and Your Care Team

If invasive cancer is detected, it is highly recommended that a specialized gastrointestinal pathologist reviews your slides to confirm the findings, as this secondary review can sometimes change the risk classification [13] [14].

Your doctor will likely refer you to a colorectal surgeon or a multidisciplinary tumor board (a team of specialists who review complex cases together) [15]. This team may recommend clinical staging. Staging often involves imaging tests like a CT scan of the chest, abdomen, and pelvis, as well as a CEA (Carcinoembryonic Antigen) blood test [16]. These tests look for radiographic or chemical evidence that the cancer has spread elsewhere. However, it is important to know that a normal CEA or a clear CT scan cannot completely rule out the presence of microscopic cancer cells in the lymph nodes.

Making the Decision: Surveillance vs. Surgery

The ultimate goal is to balance the risk of cancer returning against the physical impact and risks of major bowel surgery. This decision is highly individualized and should account for your overall health, age, and personal preferences [17].

Endoscopic Surveillance

If your cancer has highly favorable features, your team might recommend active endoscopic surveillance rather than immediate surgery. This is often an option if the polyp was removed completely in one piece (en bloc) with clearly negative margins, the cancer is well or moderately differentiated, there is no lymphovascular invasion, tumor budding is low, and the invasion is very superficial [10] [18].

Surveillance is not simply “waiting and seeing.” It involves a strict schedule of follow-up colonoscopies—often starting with an early examination of the polypectomy scar to check for residual tissue, followed by regular intervals to ensure the rest of the colon is clear [10].

Surgical Bowel Resection

If the pathology report shows high-risk features, or if the margins cannot be accurately assessed, the standard recommendation is usually to undergo a surgical bowel resection (a segmental colectomy) [10] [5]. High-risk features that typically prompt surgery include:

  • A positive or indeterminate deep margin [3] [11]
  • Deep invasion into the submucosa (such as Haggitt level 4 or depth >1000 micrometers) [5] [7]
  • Lymphovascular invasion (LVI) [9]
  • Poor differentiation [9]
  • High-grade tumor budding [9]

The purpose of surgery is to remove the section of the colon where the polyp was located to clear out any potential leftover cancer cells in the colon wall, and importantly, to remove and test the regional lymph nodes [7]. Surgery involves recovery time, potential changes in bowel function, and depending on the location of the tumor and your individual anatomy, the possibility (though not always likely) of a temporary or permanent stoma. Your surgical team will discuss these specific risks with you based on your unique situation.

Common questions in this guide

Does invasive cancer in a colon polyp mean I need surgery?
Not always. If the polyp was removed in one piece with clear margins and has no high-risk features, close colonoscopy surveillance may be reasonable; deeper invasion, cancer at the deep margin, an indeterminate margin, lymphovascular invasion, poor differentiation, high-grade tumor budding, or an unassessable specimen often leads doctors to recommend segmental colectomy.
What does invasive cancer mean compared with high-grade dysplasia in a polyp?
High-grade dysplasia or intramucosal neoplasia is limited to the inner mucosal layer, where lymphatic spread is negligible, and complete removal with clear margins is generally considered curative. Invasive cancer has crossed into the submucosa, where it can reach lymphatic or blood vessels and may require additional treatment.
Which findings on the pathology report affect what happens next?
Doctors consider whether the deep and side margins are clear, how far the cancer has entered the colon wall, and whether the specimen was removed in one piece. They also look for cancer in lymphatic or blood vessels, poor cell differentiation, and high-grade tumor budding because these findings raise concern for lymph-node involvement or residual cancer.
Why does it matter whether the polyp was removed in one piece?
A one-piece removal lets the pathologist measure invasion and evaluate the edges more reliably. When a polyp is removed in several pieces, the deep margin or true depth may be impossible to assess, so expert review and careful discussion of surgery are often needed.
What tests are usually done after invasive cancer is found?
A gastrointestinal pathologist may review the slides, and your team may order CT scans of the chest, abdomen, and pelvis plus a CEA blood test to look for evidence of spread. Clear scans and a normal CEA are reassuring but cannot completely rule out microscopic cancer in nearby lymph nodes.
What does surveillance involve if surgery is not recommended?
Surveillance means planned follow-up rather than no treatment. It commonly begins with an early colonoscopy to inspect the polypectomy scar and continues with repeat colonoscopies at intervals chosen by your care team to check the scar and the rest of the colon.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on colon adenoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has my pathology report been reviewed by a specialized gastrointestinal pathologist, and did they assess all key features like depth, margins, and tumor budding?
  2. 2.Was my polyp removed in one single piece (en bloc) or in multiple pieces (piecemeal), and how does that affect the certainty of my margins?
  3. 3.Are both the deep/vertical and lateral margins clearly negative, and what is the exact measurement in millimeters?
  4. 4.What is the exact depth of invasion (Haggitt level 4 or a measurement in micrometers) and were there any other high-risk features like lymphovascular invasion?
  5. 5.Based on my specific pathology, what is my individual risk of lymph node involvement or residual cancer if I do not have surgery?
  6. 6.If we choose surveillance, what is the exact schedule for follow-up colonoscopies, and will the remaining colon be fully evaluated?
  7. 7.Should my case be reviewed by a multidisciplinary tumor board to help weigh the risks and benefits of surgery versus surveillance?

References

References (18)
  1. 1

    Differences in the pathological diagnosis of colorectal neoplasia between the East and the West: Present status and future perspectives from Japan.

    Yao T, Shiono S

    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 2016; (28(3)):306-11 doi:10.1111/den.12535.

    PMID: 26295687
  2. 2

    Pathology definitions and resection strategies for early colorectal neoplasia: Eastern versus Western approaches in the post-Vienna era.

    Nishimura M, Saito Y, Nakanishi Y, et al.

    Gastrointestinal endoscopy 2020; (91(5)):983-988 doi:10.1016/j.gie.2019.12.021.

    PMID: 31874160
  3. 3

    Re-examining the 1-mm margin and submucosal depth of invasion: a review of 216 malignant colorectal polyps.

    Berg KB, Telford JJ, Gentile L, Schaeffer DF

    Virchows Archiv : an international journal of pathology 2020; (476(6)):863-870 doi:10.1007/s00428-019-02711-9.

    PMID: 31915959
  4. 4

    Outcomes following polypectomy for malignant colorectal polyps are similar to those following surgery in the general population.

    Lopez A, Bouvier AM, Jooste V, et al.

    Gut 2019; (68(1)):111-117 doi:10.1136/gutjnl-2016-312093.

    PMID: 29074726
  5. 5

    Histologic Factors Associated With Need for Surgery in Patients With Pedunculated T1 Colorectal Carcinomas.

    Backes Y, Elias SG, Groen JN, et al.

    Gastroenterology 2018; (154(6)):1647-1659 doi:10.1053/j.gastro.2018.01.023.

    PMID: 29366842
  6. 6

    Predictors of lymph node metastases, recurrence, and survival in patients with pedunculated-type T1 colorectal cancer.

    Kasuga K, Uraoka T, Kajiwara Y, et al.

    Journal of gastroenterology 2026; (61(2)):172-183 doi:10.1007/s00535-025-02318-9.

    PMID: 41266845
  7. 7

    Histopathological risk factors for lymph node metastases in T1 colorectal cancer: meta-analysis.

    Ebbehøj AL, Jørgensen LN, Krarup PM, Smith HG

    The British journal of surgery 2021; (108(7)):769-776 doi:10.1093/bjs/znab168.

    PMID: 34244752
  8. 8

    A three-tier classification system based on the depth of submucosal invasion and budding/sprouting can improve the treatment strategy for T1 colorectal cancer: a retrospective multicenter study.

    Kawachi H, Eishi Y, Ueno H, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2015; (28(6)):872-9 doi:10.1038/modpathol.2015.36.

    PMID: 25720321
  9. 9

    Pathological risk stratification after endoscopic resection of T1 colorectal cancer: a comparative analysis of international guidelines.

    Lim HT, Sohn DK

    Journal of minimally invasive surgery 2026; (29(1)):31-39 doi:10.7602/jmis.2026.29.1.31.

    PMID: 41847788
  10. 10

    Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2022.

    Pimentel-Nunes P, Libânio D, Bastiaansen BAJ, et al.

    Endoscopy 2022; (54(6)):591-622 doi:10.1055/a-1811-7025.

    PMID: 35523224
  11. 11

    Long-term outcomes after endoscopic removal of malignant colorectal polyps: Results from a 10-year cohort.

    Fábián A, Bor R, Vasas B, et al.

    World journal of gastrointestinal endoscopy 2024; (16(4)):193-205 doi:10.4253/wjge.v16.i4.193.

    PMID: 38680198
  12. 12

    International validation of a risk prediction algorithm for patients with malignant colorectal polyps.

    Richards C, Levic K, Fischer J, et al.

    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2020; (22(12)):2105-2113 doi:10.1111/codi.15365.

    PMID: 32931132
  13. 13

    [Guidelines for the management of malignant colo-rectal polyps (pTis and pT1) treated by endoscopic resection].

    Selves J, Terris B, Cazals-Hatem D, Fléjou JF

    Annales de pathologie 2018; (38(6)):331-337 doi:10.1016/j.annpat.2018.04.007.

    PMID: 30056944
  14. 14

    Malignant Colorectal Polyp Pathology: Are We Getting Sufficient Information to Make Decisions?

    Gimon TI, Dykstra MA, Chezar K, et al.

    Diseases of the colon and rectum 2020; (63(2)):135-142 doi:10.1097/DCR.0000000000001538.

    PMID: 31914110
  15. 15

    Exploration of between-hospital variation and the basis for decision making in management of malignant colorectal polyps- a Danish population-based study.

    Würtz HJ, Lund L, Lindebjerg J, et al.

    World journal of surgical oncology 2026; (24(1)).

    PMID: 42057017
  16. 16

    Management of Malignant Colon Polyps.

    Pedraza R, Siddharthan R

    Diseases of the colon and rectum 2021; (64(3)):262-266 doi:10.1097/DCR.0000000000001930.

    PMID: 33337601
  17. 17

    Colorectal malignant polyps: a modern approach.

    Saraiva S, Rosa I, Fonseca R, Pereira AD

    Annals of gastroenterology 2022; (35(1)):17-27 doi:10.20524/aog.2021.0681.

    PMID: 34987284
  18. 18

    Endoscopic Treatment of T1 Colorectal Cancer.

    Metter K, Weißinger SE, Várnai-Händel A, et al.

    Cancers 2023; (15(15)) doi:10.3390/cancers15153875.

    PMID: 37568691

This page is for informational purposes only and does not constitute medical advice. Your gastroenterologist, pathologist, and colorectal surgeon can interpret your report and recommend the safest next step for you.